Moderna’s COVID-19 Vaccine Price Will Be Test of US Negotiating Power
Drug pricing experts are concerned the US government may not follow through on its commitment to pay less for COVID-19 vaccines it has helped fund given reports Moderna may be pushing a $50-$60/course price. The US also has little ability to control pricing in the private market – even for some government payers.
You may also be interested in...
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
Supply agreement with the Health and Human Services Department and the Department of Defense reflects a profitable per dose price of $19.50 for an initial batch of 100 million doses of the vaccine candidate, pending FDA authorization or approval.
Ease of manufacturing scale up may determine which candidates advance furthest in the US government's partnership with industry to speed COVID-19 vaccines to patients. Senior government officials also discussed approval standards, how a vaccine would be distributed, and how much the government and Americans could pay in a 16 June press call.